MedinCell S.A. (FRA:MEB)
Germany · Delayed Price · Currency is EUR | Market Cap | 962.95M +78.4% |
| Revenue (ttm) | 32.44M +145.8% |
| Net Income | -19.95M |
| EPS | -0.63 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 26.14 |
| Previous Close | 26.10 |
| Day's Range | 25.36 - 26.14 |
| 52-Week Range | 14.74 - 37.82 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jun 16, 2026 |
About MedinCell
MedinCell S.A., a clinical-stage and commercial biopharmaceutical licensing company, develops long acting injectables in various therapeutic areas in France. The company develops solutions based on BEPO, a long-acting injectable technology. It offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults and bipolar I disorder. It is also developing mdc-TJK, a subcutaneous injection that is in the NDA preparation stage for the treatment of schizophrenia in adults; and mdc-CWM, a sustained-release formulation of celecoxib in Phase III tria... [Read more]
Financial Performance
In fiscal year 2025, MedinCell's revenue was 27.73 million, an increase of 132.12% compared to the previous year's 11.95 million. Losses were -18.44 million, -26.36% less than in 2024.
Financial StatementsNews
Medincell: Videoconference and Publication of Annual Financial Results, Tuesday, June 16, 2026
MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announ...
Medincell to Participate in Jefferies and Evercore Investor Conferences in the U.S. in June
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatme...
Teva: European Medicines Agency Accepts Marketing Authorization Application For TEV-'749
(RTTNews) - Teva Pharmaceuticals International GmbH, a unit of Teva Pharmaceutical Industries (TEVA), and Medincell announced that the European Medicines Agency has accepted the Marketing Authorizatio...
MedinCell Transcript: R&D Day 2026
Strong adoption of UZEDY and anticipated approval of olanzapine LAI validate the platform approach, while strategic partnerships and robust IP drive long-term royalty growth. Platform innovation and lifecycle management strategies expand opportunities in chronic diseases and beyond.
Medincell to Host an Online R&D Day on Tuesday, May 12, 2026
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL) will host an online R&D Day, held in English, on Tuesday, May 12, 2026, from 4:00 to 5:30 pm CEST (10:00 - 11:3...
Medincell to Present at the TD Cowen 46th Annual Healthcare Conference in Boston, March 2-4, 2026
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatme...
FDA Accepts NDA For Teva And Medincell's Olanzapine LAI In Schizophrenia Treatment
(RTTNews) - Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), together with Medincell, announced that the U.S. Food and Drug Administration (FDA) has accepted its...
Medincell - UZEDY®: Net Sales Increased from $117M in 2024 to $191M in 2025 (+63%)
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell's (Paris:MEDCL) partner, Teva Pharmaceuticals, today shared the following information in connection with the publication of its Q4 and ...
MedinCell Transcript: H1 25/26
Olanzapine LAI FDA filing and UZEDY's strong growth drive a 50% revenue increase and improved operating loss. The pipeline advances with AbbVie and Gates Foundation-backed programs, while a robust cash position supports future growth.
MedinCell Quarterly report: H1 2026
MedinCell has published its H1 2026 quarterly earnings report on December 9, 2025.
MedinCell Earnings release: H1 2026
MedinCell released its H1 2026 earnings on December 9, 2025, summarizing the period's financial results.
MedinCell Slides: H1 2026
MedinCell has posted slides in relation to its H1 2026 quarterly earnings report, which was published on December 9, 2025.
MedinCell Transcript: Evercore ISI 8th Annual HealthCONx Conference
Strong growth is expected from UZEDY and the upcoming long-acting olanzapine, which addresses key safety and compliance issues. Market adoption of LAIs is accelerating, with significant commercial potential in both the US and Europe.
MedinCell Transcript: Jefferies London Healthcare Conference 2025
A transformative period is underway, with strong UZEDY sales, a robust pipeline led by long-acting olanzapine, and global health initiatives. Profitability is targeted for 2027, with new technologies and partnerships fueling future growth.
Teva : FDA Grants Expanded Approval For UZEDY To Treat Bipolar I Disorder In Adults
(RTTNews) - Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), in collaboration with Medincell (MEDCL.PA), announced that the U.S. Food and Drug Administration has...
MedinCell Press release: Status Update
MedinCell issued a press release on September 22, 2025, disclosing material business information to investors.
Medincell Reports Positive Phase 3 Safety Data For Olanzapine LAI; No PDSS Observed
(RTTNews) - Medincell SA (MEDCL.PA) reported that new long-term safety data from the completed Phase 3 SOLARIS trial support the potential of Olanzapine LAI (TEV-749) as the first long-acting olanzapi...